NRXP NRX Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1719406 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2,076.5%
TTM net income YoY48.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin40.5%
Operating margin-551.7%
Net margin-454.1%
FCF margin—
EBITDA margin-546.4%
Returns
ROE—
ROA-92.3%
ROIC (approx.)—
Asset turnover0.20x
Leverage & solvency
Liabilities / assets107.1%
Debt / equity—
Current ratio0.76x
Interest coverage-17.37x
Cash quality & payout
Operating cash flow / net income1.19x
Accruals ratio17.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.23M | $0 | $0 | — | — |
| Cost of revenue | $505,000 | $0 | — | — | — |
| Gross profit | $720,000 | $0 | — | — | — |
| R&D expense | $3.78M | $6.20M | $13.37M | $17.03M | $20.26M |
| SG&A expense | $13.06M | $13.50M | $14.22M | $27.31M | $74.94M |
| Operating income | -$16.22M | -$18.50M | -$27.84M | -$44.34M | -$115.80M |
| Interest expense | $671,000 | $230,000 | $120,000 | — | $18,000 |
| Pretax income | — | — | — | -$39.75M | -$93.06M |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$28.62M | -$25.13M | -$30.15M | -$39.75M | -$93.06M |
| EBITDA | -$16.15M | -$18.50M | -$27.83M | -$44.33M | -$115.79M |
| EPS (basic) | -1.34 | -2.36 | -3.98 | -0.60 | -1.98 |
| EPS (diluted) | — | — | — | -0.60 | -1.98 |
| Weighted avg. shares (diluted) | — | — | — | 65.77M | 46.92M |
| Balance sheet | |||||
| Cash & equivalents | $7.80M | $1.44M | $4.59M | $20.05M | $27.61M |
| Receivables | $161,000 | $0 | — | — | — |
| Current assets | $8.89M | $3.30M | $6.88M | $25.80M | $32.71M |
| PP&E, net | $63,000 | $10,000 | — | — | — |
| Goodwill | $1.79M | $0 | — | — | — |
| Intangibles | $925,000 | $0 | — | — | — |
| Total assets | $12.96M | $3.65M | $7.32M | $25.82M | $32.73M |
| Current liabilities | $28.58M | $21.86M | $19.05M | $15.59M | $11.92M |
| Short-term debt | — | — | $9.16M | $7.70M | — |
| Long-term debt | — | — | $9.16M | $2.82M | — |
| Total debt | — | — | $18.32M | $10.53M | — |
| Total liabilities | $28.89M | $26.87M | $19.05M | $18.41M | $11.92M |
| Shareholders' equity | -$15.94M | -$23.22M | -$11.73M | $7.41M | $20.81M |
| Net debt | — | — | $13.73M | -$9.53M | — |
| Shares outstanding | 31.73M | 14.59M | 8.39M | 66.44M | 58.81M |
| Cash flow statement | |||||
| Operating cash flow | -$14.11M | -$10.64M | -$21.66M | -$39.76M | -$37.70M |
| Capital expenditure | — | $0 | $3,000 | $10,000 | $7,000 |
| Free cash flow | — | -$10.64M | -$21.66M | -$39.77M | -$37.71M |
| Investing cash flow | -$2.81M | $0 | -$3,000 | -$10,000 | -$7,000 |
| Financing cash flow | $23.28M | $7.49M | $6.20M | $32.21M | $63.46M |
| Depreciation & amortization | $70,000 | $5,000 | $5,000 | $4,000 | $2,000 |
| Stock-based compensation | $228,000 | $486,000 | $387,000 | $3.63M | $7.79M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.